Education
About Us
Working with TipRanks
Follow Us
Conmed (CNMD)
NYSE:CNMD
CNMD Stock Chart & Stats
$44.35
$0.19(0.28%)
At close: 4:00 PM EST
$44.35
$0.19(0.28%)
Day’s Range― - ―
52-Week Range$35.37 - $67.46
Previous CloseN/A
Volume49.43K
Average Volume (3M)368.83K
Market Cap
$1.29B
Enterprise Value$2.12B
Total Cash (Recent Filing)$38.93M
Total Debt (Recent Filing)$853.75M
Price to Earnings (P/E)27.6
Beta0.52
Next Earnings
May 06, 2026EPS Estimate
0.82Next Dividend Ex-DateN/A
Dividend Yield2.02%
Share Statistics
EPS (TTM)1.43
Shares Outstanding30,967,955
10 Day Avg. Volume284,080
30 Day Avg. Volume368,831
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.19
Price to Sales (P/S)1.62
P/FCF Ratio13.72
Enterprise Value/Market Cap1.64
Enterprise Value/Revenue1.57
Enterprise Value/Gross Profit2.90
Enterprise Value/Ebitda11.08
Forecast
1Y Price Target
$49.67Price Target Upside11.99% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Analyst Alignment And Earnings BeatRevenue and earnings per share exceeded analyst consensus and subsequent estimate adjustments aligned with company guidance, reinforcing credibility of the updated outlook.
Portfolio OptimizationExit of the gastroenterology product lines is expected to improve gross margins and support higher organic growth by removing lower-margin operations from the portfolio.
Supply Chain RecoveryResolution of prior supply chain constraints enabled key product lines to grow as management anticipated, supporting steadier revenue delivery across core categories.
Bears Say
Guidance Shortfall And EPS Dilution RiskCompany financial guidance came in below analyst expectations and the strategic business exit is anticipated to dilute adjusted earnings per share in 2026, prompting downgrades to future estimates.
Leadership UncertaintyDeparture of the chief financial officer without a named replacement and limited commentary during the transition increases uncertainty around financial leadership and communication.
Profitability PressureGross margin and operating margin declined year over year, indicating weakening profitability that could pressure investor sentiment and valuation.
Conmed News
CNMD FAQ
What was Conmed’s price range in the past 12 months?
Conmed lowest stock price was $35.37 and its highest was $67.46 in the past 12 months.
What is Conmed’s market cap?
Conmed’s market cap is $1.29B.
When is Conmed’s upcoming earnings report date?
Conmed’s upcoming earnings report date is May 06, 2026 which is in 83 days.
How were Conmed’s earnings last quarter?
Conmed released its earnings results on Jan 28, 2026. The company reported $1.43 earnings per share for the quarter, beating the consensus estimate of $1.324 by $0.106.
Is Conmed overvalued?
According to Wall Street analysts Conmed’s price is currently Undervalued.
Does Conmed pay dividends?
Conmed pays a Quarterly dividend of $0.2 which represents an annual dividend yield of 2.02%. See more information on Conmed dividends here
What is Conmed’s EPS estimate?
Conmed’s EPS estimate is 0.82.
How many shares outstanding does Conmed have?
Conmed has 30,967,955 shares outstanding.
What happened to Conmed’s price movement after its last earnings report?
Conmed reported an EPS of $1.43 in its last earnings report, beating expectations of $1.324. Following the earnings report the stock price went down -3.567%.
Which hedge fund is a major shareholder of Conmed?
Currently, no hedge funds are holding shares in CNMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Conmed Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$49.67 (11.99% Upside)
$49.67 (11.99% Upside)
Hedge Fund Trend
Increased
By 106.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $268.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.21%
12-Months-Change
Fundamentals
Return on Equity
6.60%
Trailing 12-Months
Asset Growth
1.87%
Trailing 12-Months
Company Description
Conmed
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
CNMD Company Deck
CNMD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear operational and strategic progress—strong adjusted results, meaningful growth in orthopedics, momentum in AirSeal/Buffalo Filter/BioBrace platforms, supply-chain improvements, and solid cash generation—against notable near-term headwinds: a sizeable GAAP earnings decline, tariff-driven margin pressure, and near-term dilution from the GI exit. Management provided constructive 2026 guidance but flagged increased SG&A and R&D investments and tariff impacts that compress near-term EPS. Overall the company appears to be executing a deliberate repositioning for longer-term, higher‑margin growth while accepting short-term earnings trade-offs.View all CNMD earnings summariesCNMD Stock 12 Month Forecast
Average Price Target
$49.67
▲(11.99% Upside)
Technical Analysis
Artivion
―
Integra Lifesciences
―
Ufp Technologies
―
AdaptHealth
―
PROCEPT BioRobotics
―
Ownership Overview
Currently, No data available
---